Skip to Content

Drug interactions between iobenguane I 131 and Ricobid-D

Results for the following 2 drugs:
iobenguane I 131
Ricobid-D (phenylephrine)

Interactions between your drugs

Major

phenylephrine iobenguane I-131

Applies to: Ricobid-D (phenylephrine) and iobenguane I 131

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with drugs that reduce catecholamine uptake or deplete catecholamine stores may interfere with iobenguane I-131 uptake into neuroendocrine tumors such as pheochromocytoma and paraganglioma that express high levels of norepinephrine transporter on their cell surfaces. Since iobenguane is similar in structure to norepinephrine and is subject to the same uptake and accumulation pathways as norepinephrine, drugs that alter norepinephrine disposition in adrenergic nerve terminals and presynaptic storage vesicles will likewise affect iobenguane. Dosimetry calculations and efficacy of iobenguane I-131 may be altered. These drugs include central nervous system stimulants (e.g., amphetamines, cocaine, methylphenidate); norepinephrine and dopamine reuptake inhibitors (e.g., phentermine); norepinephrine and serotonin reuptake inhibitors (e.g., tramadol); central monoamine depleting drugs (e.g., reserpine); nonselective beta-adrenergic blockers (e.g., labetalol); alpha agonists or alpha/beta agonists (e.g., pseudoephedrine, phenylephrine, ephedrine, phenylpropanolamine, naphazoline); monoamine oxidase inhibitors; tricyclic antidepressants; norepinephrine reuptake inhibitors (e.g., bupropion, duloxetine, mirtazapine, venlafaxine); and botanicals that may inhibit reuptake of norepinephrine, serotonin, or dopamine (e.g., ephedra, ma huang, St John's wort, yohimbine). These drugs were not permitted in clinical trials that assessed the safety and efficacy of iobenguane I-131.

MANAGEMENT: Drugs that reduce catecholamine uptake or deplete catecholamine stores should be discontinued for at least five biological half-lives before administration of either the dosimetry dose or a therapeutic dose of iobenguane I-131. Do not administer these drugs until at least 7 days after each iobenguane I-131 dose. Patients should be monitored for the occurrence of clinically significant withdrawal symptoms, especially patients with elevated levels of circulating catecholamines and their metabolites.

References

  1. "Product Information. Azedra (iobenguane I-131)." Progenics Pharmaceuticals, Inc., New York, NY.

Drug and food interactions

No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide